Sitaxentan
- Generic Name
- Sitaxentan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H15ClN2O6S2
- CAS Number
- 184036-34-8
- Unique Ingredient Identifier
- J9QH779MEM
- Background
Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.
- Indication
Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure.
- Associated Conditions
- -
- Associated Therapies
- -
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 131
- Registration Number
- NCT00796666
- Locations
- 🇺🇦
Pfizer Investigational Site, Kyiv, Ukraine
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 183
- Registration Number
- NCT00795639
- Locations
- 🇺🇦
Pfizer Investigational Site, Kyiv, Ukraine
Pharmacogenomics in Pulmonary Arterial Hypertension
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- West Penn Allegheny Health System
- Registration Number
- NCT00593905
- Locations
- 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath